{"id":373,"date":"2026-06-16T22:18:40","date_gmt":"2026-06-16T15:18:40","guid":{"rendered":"https:\/\/dnacenter.thaizone.net\/toxin-based-drug-moxetumomab-pasudotox-may-be-new-option-for-rare-leukemia\/"},"modified":"2026-06-16T22:18:40","modified_gmt":"2026-06-16T15:18:40","slug":"toxin-based-drug-moxetumomab-pasudotox-may-be-new-option-for-rare-leukemia","status":"publish","type":"post","link":"https:\/\/dnacenter.thaizone.net\/en\/toxin-based-drug-moxetumomab-pasudotox-may-be-new-option-for-rare-leukemia\/","title":{"rendered":"Toxin-Based Drug Moxetumomab Pasudotox May Be New Option for Rare Leukemia"},"content":{"rendered":"<p>&nbsp;<\/p>\n<figure class=\"image-right-medium centered-set\" style=\"box-sizing: border-box; margin-bottom: 2.5em; margin-left: 1em; padding-left: 2.5em; font-variant-numeric: inherit; font-variant-east-asian: inherit; font-stretch: inherit; line-height: inherit; font-family: &quot;Noto Sans&quot;, &quot;Century Gothic&quot;, Arial, sans-serif; vertical-align: baseline; overflow: hidden; position: relative; text-align: center; float: right; width: 329.75px; background-color: rgb(255, 255, 251); color: rgb(46, 46, 46);\">\n<div class=\"centered-element\" style=\"box-sizing: border-box; font: inherit; vertical-align: baseline; direction: ltr; display: inline-block; max-width: 100%; position: relative;\"><img decoding=\"async\" src=\"https:\/\/www.cancer.gov\/PublishedContent\/Images\/images\/research\/science\/cells\/hairy-leukemia-blood-cells-article.__v10041390.jpg\" alt=\"\" style=\"box-sizing: border-box; border-width: 0px; border-style: initial; font: inherit; vertical-align: middle; max-width: 100%; height: auto; display: block;\" \/><\/div><figcaption style=\"box-sizing: border-box; font: inherit; vertical-align: baseline;\">\n<div class=\"caption-container no-resize\" style=\"box-sizing: border-box; margin-top: -0.3125em; padding: 1.25em 0.9375em; font-style: inherit; font-variant: inherit; font-weight: inherit; font-stretch: inherit; line-height: 1.5em; font-family: Montserrat, &quot;Avant Garde&quot;, Arial, sans-serif; vertical-align: baseline; direction: ltr; background-color: rgb(245, 245, 245); text-align: left; font-size: 14px !important;\">\n<p style=\"box-sizing: border-box; font-style: inherit; font-variant: inherit; font-stretch: inherit; font-size: inherit; line-height: 1.5em; font-family: inherit; vertical-align: baseline; direction: ltr; text-rendering: optimizeLegibility;\">A peripheral blood smear showing several hairy leukemia cells.<\/p>\n<div class=\"image-photo-credit\" style=\"box-sizing: border-box; font-style: inherit; font-variant: inherit; font-weight: inherit; font-stretch: inherit; font-size: 12px; line-height: inherit; font-family: inherit; vertical-align: baseline; direction: ltr;\">Credit: Case Rep Pathol July 2014. doi: 10.1155\/2014\/497027. CC BY 3.0.<\/div>\n<\/div>\n<\/figcaption><\/figure>\n<\/p>\n<p style=\"box-sizing: border-box; margin-top: 1.25em; margin-bottom: 1.25em; font-variant-numeric: inherit; font-variant-east-asian: inherit; font-stretch: inherit; line-height: 1.5em; font-family: &quot;Noto Sans&quot;, &quot;Century Gothic&quot;, Arial, sans-serif; vertical-align: baseline; direction: ltr; text-rendering: optimizeLegibility; color: rgb(46, 46, 46); background-color: rgb(255, 255, 251);\">People diagnosed with hairy cell leukemia (HCL), an uncommon form of leukemia, may soon have an effective new treatment option, according to findings from an international phase 3 clinical trial. In the trial, three-quarters of people with HCL that had come back or progressed after earlier treatment&nbsp;<a class=\"definition\" href=\"https:\/\/www.cancer.gov\/Common\/PopUps\/popDefinition.aspx?id=CDR0000044085&amp;version=Patient&amp;language=English\" style=\"box-sizing: border-box; border-width: 0px 0px thin; border-top-style: initial; border-right-style: initial; border-bottom-style: dotted; border-left-style: initial; font: inherit; vertical-align: baseline; color: rgb(46, 46, 46);\">responded<\/a>&nbsp;to treatment with the toxin-based drug&nbsp;<a href=\"https:\/\/www.cancer.gov\/publications\/dictionaries\/cancer-drug\/def\/moxetumomab-pasudotox\" style=\"box-sizing: border-box; border-width: 0px; border-style: initial; font: inherit; vertical-align: baseline; color: rgb(43, 123, 186);\">moxetumomab pasudotox<\/a><span style=\"box-sizing: border-box; font: inherit; vertical-align: baseline;\">&nbsp;(Moxe)<\/span>.<\/p>\n<p style=\"box-sizing: border-box; margin-top: 1.25em; margin-bottom: 1.25em; font-variant-numeric: inherit; font-variant-east-asian: inherit; font-stretch: inherit; line-height: 1.5em; font-family: &quot;Noto Sans&quot;, &quot;Century Gothic&quot;, Arial, sans-serif; vertical-align: baseline; direction: ltr; text-rendering: optimizeLegibility; color: rgb(46, 46, 46); background-color: rgb(255, 255, 251);\">The&nbsp;<a href=\"https:\/\/meetinglibrary.asco.org\/record\/161664\/abstract\" style=\"box-sizing: border-box; border-width: 0px; border-style: initial; font: inherit; vertical-align: baseline; color: rgb(43, 123, 186);\">disease disappeared completely during treatment<\/a><a class=\"icon-exit-notification\" title=\"Exit Disclaimer\" href=\"https:\/\/www.cancer.gov\/policies\/linking\" style=\"box-sizing: border-box; margin-right: 0.25em; margin-left: 0.25em; border-width: 0px; border-style: initial; font: inherit; vertical-align: baseline; color: rgb(43, 123, 186); display: inline-block; background-image: url(&quot;\/publishedcontent\/images\/images\/design-elements\/sprites\/svg-sprite.__v15301131.svg&quot;); background-size: 11.625em 256.875em; width: 0.93769em; height: 0.8125em; background-position: 5.88246% 29.8584%;\"><span class=\"hidden\" style=\"box-sizing: border-box; margin: -1px; font: inherit; vertical-align: baseline; clip: rect(0px, 0px, 0px, 0px); height: 1px; overflow: hidden; position: absolute; width: 1px;\">Exit Disclaimer<\/span><\/a>&nbsp;in 33 of the 80 patients (41%), and more than 70% of these patients remained cancer free after 6 months of follow-up. The trial results were presented June 2 at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.<\/p>\n<p style=\"box-sizing: border-box; margin-top: 1.25em; margin-bottom: 1.25em; font-variant-numeric: inherit; font-variant-east-asian: inherit; font-stretch: inherit; line-height: 1.5em; font-family: &quot;Noto Sans&quot;, &quot;Century Gothic&quot;, Arial, sans-serif; vertical-align: baseline; direction: ltr; text-rendering: optimizeLegibility; color: rgb(46, 46, 46); background-color: rgb(255, 255, 251);\">&quot;This drug offers an option for patients with&nbsp;<a class=\"definition\" href=\"https:\/\/www.cancer.gov\/Common\/PopUps\/popDefinition.aspx?id=CDR0000045866&amp;version=Patient&amp;language=English\" style=\"box-sizing: border-box; border-width: 0px 0px thin; border-top-style: initial; border-right-style: initial; border-bottom-style: dotted; border-left-style: initial; font: inherit; vertical-align: baseline; color: rgb(46, 46, 46);\">relapsed<\/a>&nbsp;or&nbsp;<a class=\"definition\" href=\"https:\/\/www.cancer.gov\/Common\/PopUps\/popDefinition.aspx?id=CDR0000350245&amp;version=Patient&amp;language=English\" style=\"box-sizing: border-box; border-width: 0px 0px thin; border-top-style: initial; border-right-style: initial; border-bottom-style: dotted; border-left-style: initial; font: inherit; vertical-align: baseline; color: rgb(46, 46, 46);\">refractory<\/a>&nbsp;hairy cell leukemia that avoids additional chemotherapy and also has the potential to provide better long-term outcomes,&quot; said Robert Kreitman, M.D., of NCI&rsquo;s&nbsp;<a href=\"https:\/\/ccr.cancer.gov\/\" style=\"box-sizing: border-box; border-width: 0px; border-style: initial; font: inherit; vertical-align: baseline; color: rgb(43, 123, 186);\">Center for Cancer Research<\/a>&nbsp;(CCR), who led the trial.<\/p>\n<p style=\"box-sizing: border-box; margin-top: 1.25em; margin-bottom: 1.25em; font-variant-numeric: inherit; font-variant-east-asian: inherit; font-stretch: inherit; line-height: 1.5em; font-family: &quot;Noto Sans&quot;, &quot;Century Gothic&quot;, Arial, sans-serif; vertical-align: baseline; direction: ltr; text-rendering: optimizeLegibility; color: rgb(46, 46, 46); background-color: rgb(255, 255, 251);\">&nbsp;<\/p>\n<address style=\"text-align: right;\"><a href=\"https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2018\/hairy-cell-leukemia-moxetumomab\" target=\"_blank\">More Details<\/a><\/address>","protected":false},"excerpt":{"rendered":"<p>&nbsp; A peripheral blood smear showing several hairy leukemia cells. Credit: Case Rep Pathol July 2014. doi: 10.1155\/2014\/497027. CC BY 3.0. People diagnosed with hairy cell<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-373","post","type-post","status-publish","format-standard","hentry","category-5"],"_links":{"self":[{"href":"https:\/\/dnacenter.thaizone.net\/en\/wp-json\/wp\/v2\/posts\/373","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dnacenter.thaizone.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dnacenter.thaizone.net\/en\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/dnacenter.thaizone.net\/en\/wp-json\/wp\/v2\/comments?post=373"}],"version-history":[{"count":0,"href":"https:\/\/dnacenter.thaizone.net\/en\/wp-json\/wp\/v2\/posts\/373\/revisions"}],"wp:attachment":[{"href":"https:\/\/dnacenter.thaizone.net\/en\/wp-json\/wp\/v2\/media?parent=373"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dnacenter.thaizone.net\/en\/wp-json\/wp\/v2\/categories?post=373"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dnacenter.thaizone.net\/en\/wp-json\/wp\/v2\/tags?post=373"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}